Critical Review: Regenxbio (NASDAQ:RGNX) & Aevi Genomic Medicine (NASDAQ:GNMX)

Share on StockTwits

Regenxbio (NASDAQ:RGNX) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Regenxbio and Aevi Genomic Medicine, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regenxbio 0 3 5 0 2.63
Aevi Genomic Medicine 0 1 0 0 2.00

Regenxbio currently has a consensus price target of $79.13, indicating a potential upside of 109.60%. Given Regenxbio’s stronger consensus rating and higher possible upside, research analysts clearly believe Regenxbio is more favorable than Aevi Genomic Medicine.


This table compares Regenxbio and Aevi Genomic Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Regenxbio -88.57% -15.39% -14.50%
Aevi Genomic Medicine N/A -347.53% -202.79%

Valuation & Earnings

This table compares Regenxbio and Aevi Genomic Medicine’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Regenxbio $218.51 million 6.36 $99.94 million $2.38 15.86
Aevi Genomic Medicine N/A N/A -$30.77 million ($0.50) -0.27

Regenxbio has higher revenue and earnings than Aevi Genomic Medicine. Aevi Genomic Medicine is trading at a lower price-to-earnings ratio than Regenxbio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Regenxbio has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

Insider & Institutional Ownership

79.5% of Regenxbio shares are owned by institutional investors. Comparatively, 7.3% of Aevi Genomic Medicine shares are owned by institutional investors. 13.8% of Regenxbio shares are owned by company insiders. Comparatively, 43.8% of Aevi Genomic Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


Regenxbio beats Aevi Genomic Medicine on 11 of the 13 factors compared between the two stocks.

Regenxbio Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with's FREE daily email newsletter.